What is the current stock price of Cryo-Cell International, Inc. (CCEL)?

As of the latest market data, Cryo-Cell International, Inc. (CCEL) is trading at $3.47. The stock has seen a loss of -6.22% today.

Does Cryo-Cell International, Inc. (CCEL) pay a dividend?

Based on current data, Cryo-Cell International, Inc. does not have a confirmed active dividend policy.

What is the market cap of Cryo-Cell International, Inc.?

The current market capitalization of Cryo-Cell International, Inc. (CCEL) is approximately unavailable.

CCEL

Cryo-Cell International, Inc.·Healthcare

3.47

6.216%(−0.23)

Market Closed

4.30

23.919%(+0.83)

After Hours

Last Updated: — ET

52W L: $2.7252W H: $6.35

CCEL NEWS

defenseworld.net

Apr 3

Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – Should You Sell?

Shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $3.82 and traded as low as $3.48. Cryo-Cell International shares last traded at $3.64, with a volume of 7,996 shares changing hands. Cryo-Cell International Price Performance

businesswire.com

Mar 12

Cryo-Cell Receives NYSE American Continued Listing Notice

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in com.

businesswire.com

Feb 27

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue.

Company Profile

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Sector

Healthcare

Industry

Medical - Care Facilities

Employees

IPO Date

1994-04-04

Beta

0.63

Websitewww.cryo-cell.com↗